Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: West Coast VC Invests Up to $15M in Software-Driven Devices and Diagnostics & Digital Health Companies in the USA

17 Jan

A venture capital firm based in California is interested in making equity investments into early stage companies with investments ranging from $1M to $15 million per company, depending on the company’s needs and stage of development. The firm is currently seeking investment opportunities throughout the United States.

The firm is looking for companies operating in the HIT/ Digital Health space as well as diagnostics and devices with a software component. The firm is entirely opportunistic in terms of indication and will consider companies at all stages of development. Specific areas of interest include life science tools, mental health, digital therapeutics, synthetic biology and 3D printing.

The firm is looking for privately held companies with strong management teams. The firm is able to provide entrepreneurs with a 200-person advisory network and bring deep operational expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Corporate Venture Firm Seeks to Invest Broadly Across Life Sciences, with Strongest Interests in Novel Drug Delivery Systems

3 Jan

A corporate venture arm of a leading electronic solutions provider looks at life sciences as one of their main focus areas. The firm focuses on strategic investments in which the corporate could bring significant value, and those that supplement the corporate’s business areas. The firm invests up to $10M over the lifetime of the company, usually between Series A to C rounds but looks even earlier for life science-related opportunities. The firm usually invests around $5M initially and reserves capital for follow-on investment. The corporate has a global footprint, with manufacturing plants throughout USA, China, and Thailand. The firm is open to global opportunities including those in rapidly growing markets like China and India. The firm is expecting to close 3 new investments in Q1 2019.

Within the early-stage life sciences ecosystem, the firm is most interested in novel drug delivery systems with target indications including oncology, cardiovascular, diabetes, and COPD. The firm also has a strong interest in technologies with a connected health component. The firm is open to all early-stage opportunities that are relevant to the firm’s focus areas, but those who do not yet have a working prototype would be considered too early for the firm. The firm is open to all classes of devices including 510k and PMA.

The firm can act as either the lead or co-investor. The firm would prefer to see companies that already have some sort of commercial engagement established. The firm aims to bring strategic value into their portfolio companies, such as working on product design and development. If the company already has such manufacturing partnership established, it is unlikely for the firm to invest in the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate: Global Investment Firm Invests Up to $25M in USA-Based Life Science Companies with High Growth Potential

3 Jan

A global investment firm founded in 2005 has about $300 AUM and invests in a wide variety of sectors, with healthcare being one of the major areas of interest. The firm can invest anywhere from $0.25 – 25M, depending on the company’s stage of development. Currently, the firm is primarily investing in USA-based opportunities.

The firm is opportunistic in terms of technology and indication and will consider all types of technologies with high growth potential, in therapeutics, medical devices, diagnostics, and digital health sectors. The firm is the largest stakeholder in a late-clinical-stage therapeutics company, but the firm is certainly open to pre-clinical therapeutics companies as well.

The firm no specific management team requirements. The firm often leads investment rounds, but is also open to co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: